6.11 Patients with residual metastatic disease or progressive 
disease after bone marrow transplant will be offered 
treatment with vinblastine chemotherapy provided their 
ANC > 1 500/jil and pits >90,000/jil. SGOT, SGPT and 
total bilirubin must be 2x normal. Vinblastine will be 
administered by continuous I.V. infusion at 1.5 
mg/M2/day for 5 days by a central venous catheter. 
Treatment with vinblastine will be repeated every 21 
days. 
Administration: Vinblastine will be given as a 
continuous infusion over 120 hours through central 
venous access. In the inpatient setting, a 24-hour supply 
of vinblastine will be admixed in 250 mg of 0.9% NaCI 
and administered via infusion pump. Bags will be 
exchanged daily for 5 days (120 hours). In the outpatient 
setting, a 24-hour supply of vinblastine will be diluted 
to a final volume of 90 ml with 0.9% NaCI. The 24-hour 
cassette will be exchanged daily for a total of 5 
cassettes per 120 hour infusion. If deemed feasible, a 
60-hour supply may be diluted to a final volume of 100 
mL with 0.9% NaCI and placed in a single cassette to be 
infused over 60 hours (40 ml per 24 hours or 1.67 ml/hr) 
requiring two cassettes over the 5 day treatment period. 
It is suggested that the infusion start early in the 
morning (around 9:00 - 10:00 A.M.), and the cassette 
exchange will occur at the opposite time on the third 
calendar day from the start of the infusion. All 
outpatient infusions will be administered via a portable 
infusion device (Pharmacia CADD-1TM). Patients will be 
instructed on the use and care of this pump. 
Recombinant DNA Research, Volume 16 
[ 111 ] 
